Meeting
2017 ASCO Annual Meeting
SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer.
Authors
Richard D. Kim
H. Lee Moffitt Cancer Center, Tampa, FL
Richard D. Kim , Shannon L McDonough , Anthony B. El-Khoueiry , Tanios S. Bekaii-Saab , Stacey Stein , Vaibhav Sahai , George P. Keogh , Edward Jae-hoon Kim , Ari David Baron , Abby B. Siegel , Afsaneh Barzi , Katherine Guthrie , Milind M. Javle , Howard S. Hochster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
02042443
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4016)
DOI
10.1200/JCO.2017.35.15_suppl.4016
Abstract #
4016
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.
First Author: Richard D. Kim
Poster
2017 Gastrointestinal Cancers Symposium
Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.
First Author: Makoto Ueno
Poster
2016 Gastrointestinal Cancers Symposium
Long-term responders to palliative chemotherapy for advanced biliary tract cancer.
First Author: Mark Doherty
Poster
2015 ASCO Annual Meeting
Gemcitabine (G), capecitabine (C) and bevacizumab (BV) in patients with advanced biliary cancers (ABC): final results of a multicenter phase II study.
First Author: Renuka V. Iyer